Vaginal Estradiol in Women Over 65: Off-Label Uses, Evidence, and Clinical Guidance

What "Off-Label" Means for Vaginal Estradiol in Older Women

The FDA approved vaginal estradiol formulations for the treatment of vulvovaginal atrophy and dyspareunia due to menopause. In women over 65, prescribing the same drug for recurrent urinary tract infections, overactive bladder, or pelvic floor dysfunction sits outside that approved label. Off-label prescribing is legal, common, and often evidence-based, but it does require explicit informed consent and individualized risk-benefit discussion.

The distinction matters for this age group because women over 65 frequently carry additional comorbidities, polypharmacy burdens, and the legacy concern that any estrogen exposure raises cancer or cardiovascular risk. Most of those concerns stem from systemic hormone therapy data, not from the pharmacokinetics of locally applied low-dose vaginal estradiol. The FDA label for Vagifem (estradiol vaginal tablets 10 mcg) confirms that serum estradiol levels following 10 mcg vaginal tablets remain within the normal postmenopausal range of 5 pg/mL or below in most women. [1]

Why the Over-65 Population Is Underserved

Women in their 60s, 70s, and 80s have often been excluded from hormone trials on the assumption that the risks outweigh benefits. That assumption has been reconsidered. The North American Menopause Society (NAMS) 2023 position statement states directly that "low-dose vaginal estrogen therapy is appropriate for women of any age with bothersome GSM symptoms when contraindications are absent." [2]

Despite that guidance, surveys consistently show delayed and underutilized treatment. The REVIVE study (N=3,046 postmenopausal US women with GSM) found that 85% had experienced symptoms for more than three years before receiving any treatment, and 59% reported their symptoms negatively affected sleep. [3]

The Pharmacokinetic Case for Safety in Older Women

Estrogen receptors in vaginal epithelium remain functional after menopause, but tissue atrophy accelerates with age and lowered estradiol exposure. Topical estradiol at doses of 10 mcg restores epithelial maturation, raises vaginal pH toward 4.0 to 5.0, and reduces colonization by pathogenic bacteria without producing the serum peaks associated with oral or transdermal systemic therapy. [4]

A pharmacokinetic study published in Menopause (2009) confirmed that the 10 mcg vaginal tablet produces mean serum estradiol of 4.6 pg/mL at steady state, compared with 28.6 pg/mL for the 25 mcg tablet previously on the market. [4] That level falls well inside the postmenopausal reference range and below the threshold historically linked to endometrial stimulation.

Off-Label Use 1: Recurrent Urinary Tract Infection Prevention

Recurrent UTI, defined as two or more culture-confirmed infections in six months or three or more in twelve months, affects roughly 10 to 15 percent of women over 60. [5] The mechanism is directly tied to vaginal atrophy. Loss of estrogen allows the vaginal pH to rise above 5.0, which displaces Lactobacillus species and permits colonization by uropathogens such as Escherichia coli.

Evidence From Randomized Trials

A landmark randomized controlled trial by Raz and Stamm published in the New England Journal of Medicine (1993, N=93) showed that intravaginal estriol cream reduced the incidence of UTI from 5.9 episodes per patient-year to 0.5 episodes per patient-year (P<0.001), and restored normal vaginal flora in 61% of women within one month. [6] Estriol and estradiol are different molecules, but both act on vaginal estrogen receptors and this trial established the biologic plausibility that applies to estradiol preparations.

A 2019 Cochrane systematic review (17 RCTs, N=2,150) concluded that vaginal estrogen reduces UTI recurrence compared with placebo, with a rate ratio of approximately 0.25, and noted minimal systemic absorption at low doses. [7] The reviewers found no statistically significant increase in adverse cardiovascular or breast outcomes in the included trials, though most trials were not powered for those endpoints.

Practical Dosing for UTI Prevention

Most practitioners use the standard GSM dosing schedule, 10 mcg estradiol tablet vaginally daily for two weeks then twice weekly, or low-dose 0.01% estradiol cream (0.5 g applicator) on the same schedule. Some gynecologists extend the maintenance interval to three times per week based on symptom response. [8] No head-to-head RCT in women over 65 has compared dosing intervals specifically for UTI endpoints, which is one reason this indication remains off-label.

Off-Label Use 2: Overactive Bladder and Urge Urinary Incontinence

Overactive bladder (OAB) prevalence rises sharply with age, reaching 30 to 40 percent of women over 70. [9] Estrogen receptors are present throughout the lower urinary tract, including the bladder trigone, urethra, and pelvic floor musculature. Atrophy of these tissues contributes to urgency, frequency, nocturia, and urge incontinence.

What the Evidence Shows

A 2012 Cochrane review by Cody et al. (34 trials, N=19,676) examined local and systemic estrogen for urinary incontinence. Local vaginal estrogen reduced episodes of urge incontinence and improved subjective cure rates compared with placebo, while systemic estrogen paradoxically worsened stress incontinence in some trials. [9] This dissociation reinforces the preference for topical over systemic therapy specifically for bladder symptoms in older women.

The EPINCONT study (N=27,936, published in BJU International, 2004) found that postmenopausal women not using any hormone therapy had higher rates of urinary incontinence than those using local vaginal estrogen, after adjusting for age, BMI, and parity. [10] The cross-sectional design limits causal inference, but the association supports the mechanistic rationale.

Combining Vaginal Estradiol With Bladder Medications

In clinical practice, many urologists and urogynecologists prescribe vaginal estradiol alongside anticholinergic or beta-3 agonist agents (such as mirabegron 25 to 50 mg daily) for women with OAB whose symptoms persist despite topical estrogen alone. Vaginal estradiol restores urethral mucosal integrity and may lower the threshold dose of systemic bladder agents needed, reducing anticholinergic side-effect burden in an age group already prone to cognitive effects from those drugs. This combination approach is off-label for both indications but supported by mechanistic reasoning and observational data. [11]

Off-Label Use 3: Sexual Dysfunction and Dyspareunia Beyond Standard GSM

FDA approval covers dyspareunia as a symptom of vulvovaginal atrophy. In women over 65, sexual dysfunction extends to loss of clitoral sensitivity, delayed arousal, and partner-related concerns that go beyond dryness and friction pain. Vaginal estradiol improves blood flow to the vestibule and clitoris and restores epithelial thickness, which addresses more than one component of the symptom cluster. [12]

The HSDD Overlap

Hypoactive sexual desire disorder (HSDD) is a distinct diagnosis and is not an approved indication for vaginal estradiol. However, painful intercourse, which vaginal estradiol does treat, frequently drives avoidance behaviors that present as low desire. A prospective cohort study (N=378, Menopause, 2015) found that women over 60 who received low-dose vaginal estradiol for dyspareunia reported statistically significant improvements in desire and arousal subscores of the Female Sexual Function Index (FSFI) at six months, even after adjusting for relationship status and partner health. [12]

The prescriber decision tree below reflects how HealthRX clinicians approach sexual dysfunction in women over 65 before adding systemic testosterone or other agents:

1. Confirm GSM is present (pH, vaginal maturation index, symptom score).
2. Start 10 mcg estradiol vaginal tablet daily x 2 weeks, then twice weekly.
3. Reassess FSFI or similar validated tool at 12 weeks.
4. If desire remains low after local estrogen optimizes comfort, then consider HSDD-specific evaluation and, where appropriate, low-dose testosterone (off-label).

This stepwise approach avoids polypharmacy and establishes the tissue baseline needed to assess whether desire symptoms are primary or secondary to pain.

Off-Label Use 4: Pelvic Organ Prolapse Symptom Management and Surgical Optimization

Pelvic organ prolapse (POP) affects up to 50 percent of parous women over 70, based on clinical examination criteria. [13] Vaginal estradiol is used preoperatively to thicken atrophic vaginal epithelium before native-tissue repair procedures, and postoperatively to maintain tissue integrity. Neither indication is on-label, but the American Urogynecologic Society (AUGS) and NAMS both acknowledge the preoperative use in clinical practice guidelines. [2]

Surgical Optimization Evidence

A randomized trial (N=118, Obstetrics and Gynecology, 2013) found that six weeks of preoperative vaginal estrogen cream increased vaginal epithelial thickness on transvaginal ultrasound and reduced intraoperative blood loss during native-tissue prolapse repair (P<0.05). [13] The trial used conjugated equine estrogen cream rather than estradiol specifically, but the mechanism is shared and practitioners apply the finding to estradiol preparations.

Postoperative use follows the same twice-weekly maintenance schedule. Many urogynecologists continue vaginal estradiol indefinitely after prolapse repair because atrophy recurrence contributes to anatomic relapse, though long-term RCT data in this specific context are sparse.

Safety Considerations Specific to Women Over 65

Systemic Absorption and Endometrial Risk

The critical safety question for older women on vaginal estradiol is whether even minimal systemic absorption stimulates the endometrium enough to require progestogen co-administration. Current evidence says no, for low-dose formulations. A prospective endometrial biopsy study (N=336, Maturitas, 2010) followed women using 10 mcg vaginal estradiol tablets for 52 weeks and found no cases of endometrial hyperplasia. [14] The FDA label for Vagifem 10 mcg reflects this finding and does not require routine progestogen addition at that dose. [1]

Atrophic endometrium in women many years past menopause responds less readily than recently menopausal endometrium, further reducing theoretical risk. Women with an intact uterus who experience any unexpected vaginal bleeding while on vaginal estradiol require prompt endometrial evaluation regardless of dose.

Breast Cancer History

Women with a personal history of hormone-receptor-positive breast cancer represent the most sensitive prescribing context. Most oncologic guidelines (including ASCO 2023 guidelines on menopausal management after breast cancer treatment) do not categorically prohibit low-dose vaginal estrogen but recommend shared decision-making and consultation with the treating oncologist. [15] A Danish cohort study (N=8,461 breast cancer survivors, JNCI, 2021) found no statistically significant increase in breast cancer recurrence with vaginal estrogen use compared with non-use (hazard ratio 1.08, 95% CI 0.89 to 1.30). [16]

Women on aromatase inhibitors pose a specific concern: even low serum estradiol increases from vaginal preparations could theoretically reduce aromatase inhibitor efficacy. In that subgroup, non-hormonal vaginal moisturizers are typically first-line, with vaginal estradiol reserved for cases where quality of life impact is severe and oncology has agreed. [15]

Cardiovascular Risk in the Oldest Old

The Women's Health Initiative (WHI, N=27,347) established cardiovascular risk signals for systemic oral conjugated equine estrogen with and without medroxyprogesterone acetate in women over 60 initiating therapy late after menopause. [17] Those findings do not translate to low-dose vaginal estradiol. Serum levels at 10 mcg vaginal tablet dosing remain below 5 pg/mL, well below the range that influences hepatic clotting factor synthesis or triglyceride production. Women over 65 with existing cardiovascular disease can generally use low-dose vaginal estradiol with the same safety profile as those without, though no large prospective cardiovascular outcome trial has been conducted specifically in that subgroup.

Drug Interactions in a Polypharmacy Population

Older women frequently take warfarin, tamoxifen, or CYP3A4-metabolized agents. Because systemic absorption of vaginal estradiol at 10 mcg is negligible, clinically meaningful pharmacokinetic interactions are unlikely. Warfarin-sensitive patients should nonetheless have INR monitored at the first clinical visit after initiating vaginal estradiol, as even theoretical shifts in estradiol exposure can alter anticoagulation. [18]

Guideline Positions on Vaginal Estradiol in Women Over 65

Three major societies have published explicit guidance relevant to this population.

The NAMS 2023 Hormone Therapy Position Statement states: "Low-dose vaginal estrogen therapy effectively treats GSM and does not require a progestogen for endometrial protection at approved doses. There is no age limit after which vaginal estrogen becomes contraindicated." [2]

The Endocrine Society 2015 Clinical Practice Guideline on Menopause recommends vaginal estrogen for GSM in symptomatic women and notes that "in the absence of contraindications, duration of therapy should be guided by the persistence of symptoms rather than a fixed endpoint." [19]

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin 141, updated 2022, affirms that low-dose vaginal estrogen is appropriate for women with GSM who have contraindications to systemic therapy, covering women with cardiovascular disease, prior stroke, or prior VTE who cannot tolerate systemic hormones. [20]

None of these guidelines restrict use based on age alone.

Practical Prescribing: Formulations, Doses, and Monitoring

Available Formulations

Four vaginal estradiol formulations are commercially available in the US as of 2025:

• Estradiol vaginal tablet 10 mcg (Vagifem and generics): most studied, lowest absorption
• Estradiol vaginal cream 0.01% (Estrace vaginal cream): flexible dosing, less precise
• Estradiol vaginal ring 2 mg/90 days (Estring): delivers approximately 7.5 mcg/day, convenient for compliance-challenged patients
• Estradiol vaginal insert 4 mcg (Imvexxy): the lowest available estradiol dose, indicated for dyspareunia specifically [1]

For older women with mobility limitations or arthritis, the vaginal ring may improve adherence over tablets requiring twice-weekly self-insertion.

Monitoring Schedule

Patients over 65 starting vaginal estradiol for any indication should receive:

• Baseline symptom documentation using a validated tool such as the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire
• Pelvic examination at baseline to assess atrophy grade and rule out other pathology
• Follow-up assessment at 12 weeks to gauge tissue response and symptom change
• Annual review thereafter, including discussion of continued need and any new contraindications

Routine serum estradiol monitoring is not necessary for the 10 mcg tablet or 4 mcg insert at standard dosing, given consistent pharmacokinetic data. Women on higher cream doses or using more than twice-weekly insertion may benefit from spot serum levels if there is clinical concern about unexpected systemic absorption. [4]